PoC clinical study of ZPL-3893787 on pruritus and inflammation in atopic dermatitis

A small biotech company in Kent is testing a new pill, ZPL-3893787, to stop the relentless itch and inflammation of eczema in a proof-of-concept clinical trial. Chronic itch—persisting for at least six weeks—affects people from infancy to old age. It disrupts sleep, alters mood, and increases the risk of other illnesses. Current treatments often fail to control both the itch and the underlying inflammation, leaving millions of patients without reliable relief. ZPL-3893787 targets both symptoms simultaneously. It has already been tested in over 50 healthy adults across two countries, and this UK Government-backed study will now assess its effects in eczema patients specifically. If the trial succeeds, ZPL-3893787 could become a new oral treatment for atopic dermatitis, one of the most common forms of eczema. Because itch and inflammation are shared features of many diseases—from psoriasis to liver disease—a drug that works here might eventually be repurposed for other conditions. That could change how doctors manage chronic itch across entire patient populations, from young children to the elderly, rather than treating each disease in isolation.